{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.1","upperLimit":"42.3","value":"24.2"}]}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.0","upperLimit":"51.8","value":"33.3"}]}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.9","upperLimit":"57.9","value":"39.4"}]}],"title":"Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.3","upperLimit":"45.5","value":"27.3"}]}],"title":"Month 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"This refers to the percentage of participants with the normalization of insulin-like growth factor-1 (IGF-1) to within normal limits by visit.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients randomized regardless of pasireotide LAR dose.","id":"OG000","title":"Pasireotide LAR - All Participants"}],"paramType":"NUMBER","populationDescription":"FAS: Comprises all patients to whom study treatment has been assigned by randomization. According to the intent to treat principle, patients were analyzed according to the study treatment they have been assigned to during the randomization procedure.","reportingStatus":"POSTED","timeFrame":"Months 3, 6, 9, 12","title":"Percentage of Overall Participants With the Normalization of IGF-1 by Visit (Core Phase)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}